Skip to main content
Clinical Trials/NCT05288751
NCT05288751
Active, not recruiting
Not Applicable

Contingency Management as a Treatment for Opioid Use Disorder and Stimulant Use Disorder in a Primary Care Setting

University of Minnesota1 site in 1 country56 target enrollmentJune 15, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Opioid Use Disorder
Sponsor
University of Minnesota
Enrollment
56
Locations
1
Primary Endpoint
Preliminary efficacy of CM on clinical outcomes: Visit Frequency
Status
Active, not recruiting
Last Updated
7 months ago

Overview

Brief Summary

Contingency management (CM) is a behavioral intervention that involves incentivizing participants for target behaviors in a clinical setting. When applied to the treatment of substance use disorders, it has demonstrated efficacy in reducing the number of urine toxicology screens positive for illicit substances and increased engagement in treatment programs. However, there is a need to translate CM treatment to primary care settings. This study will implement and assess a CM program for patients with opioid use disorder, with or without comorbid stimulant use disorder, initiating outpatient addiction medicine services at a family medicine residency clinic. Eligible patients will earn monetary incentives for attending addiction medicine appointments and abstaining from substances during outpatient treatment. Data gathered from this pilot program will be used to improve patient outcomes, treatment, and retention for persons receiving medications for opioid use disorder (MOUDs) in a primary care setting.

Registry
clinicaltrials.gov
Start Date
June 15, 2022
End Date
August 31, 2026
Last Updated
7 months ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • At least 18 years of age
  • Diagnosis of Opioid Use Disorder and/or Stimulant Use Disorder
  • Recently initiated medications for opioid use disorder (MOUDs) at Broadway Family Medicine (BFM), within 2 weeks of recruitment
  • Have an active prescription for buprenorphine-naloxone (Suboxone)

Exclusion Criteria

  • Prescription for an amphetamine would exclude patients from the abstinence-based CM, but they could participate in the attendance-only CM.
  • Dementia, development disabilities, or cognitive functioning that is too low to participate in study measures, as determined by chart review and consultation with overseeing physician.

Outcomes

Primary Outcomes

Preliminary efficacy of CM on clinical outcomes: Visit Frequency

Time Frame: 30 days post-intervention

Number of completed clinical visits per patient during the CM program.

Feasibility of CM for OUD in primary care: Retention

Time Frame: 30 days post-intervention

Of those patients who enroll in the intervention study, the percent that complete the CM intervention period.

Preliminary efficacy of CM on clinical outcomes: Urine toxicology

Time Frame: 30 days post-intervention

Percentage of UDS results that are negative for stimulants during the CM intervention period.

Feasibility of CM for OUD in primary care: Recruitment

Time Frame: 30 days post-intervention

percentage of patients invited to participate enroll in the treatment intervention.

Study Sites (1)

Loading locations...

Similar Trials